Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

23.7%

14 terminated/withdrawn out of 59 trials

Success Rate

74.5%

-12.0% vs industry average

Late-Stage Pipeline

17%

10 trials in Phase 3/4

Results Transparency

80%

33 of 41 completed trials have results

Key Signals

1 recruiting33 with results12 terminated

Enrollment Performance

Analytics

Phase 1

26(44.1%)

Phase 2

23(39.0%)

Phase 3

10(16.9%)

59Total

Phase 1(26)

Phase 2(23)

Phase 3(10)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (59)

Showing 20 of 59 trials

NCT06340360Phase 2Active Not Recruiting

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)

Role: lead

NCT06136741Phase 2Active Not Recruiting

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

Role: lead

NCT05359211Phase 1Active Not Recruiting

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Role: collaborator

NCT05632809Phase 2Recruiting

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

Role: collaborator

NCT05676749Phase 1Terminated

C-TIL051 in Non-Small Cell Lung Cancer

Role: collaborator

NCT04616196Phase 1Completed

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Role: lead

NCT03635983Phase 3Completed

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Role: collaborator

NCT05664217Phase 2Terminated

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Role: lead

NCT04209114Phase 3Completed

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Role: collaborator

NCT04433585Phase 2Completed

A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)

Role: lead

NCT04936841Phase 2Terminated

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

Role: collaborator

NCT04646044Phase 1Completed

A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19

Role: lead

NCT04540705Phase 1Completed

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

Role: collaborator

NCT04081350Phase 1Completed

A Study of LY3471851 in Participants With Eczema

Role: lead

NCT04119557Phase 1Completed

A Study of LY3471851 in Participants With Psoriasis

Role: lead

NCT02312622Phase 2Completed

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Role: collaborator

NCT04998487Phase 1Completed

A Single-Dose Study of LY3471851 in Healthy Participants